On 5 October 2016, the members of the AMYPAD project announced the start of this novel research initiative during a kick-off meeting in London. This research initiative, which includes 15 academics and private research partners, aims to investigate the value of ß-amyloid using positron emission tomography (PET) imaging as a diagnostic and therapeutic marker for Alzheimer’s disease (AD). AMYPAD is a 5 year programme, which is part of the Innovative Medicines Initiative, a joint undertaking between the European Union and the European Federation of Pharmaceutical Industries and Associations, EFPIA.
By studying the value of PET imaging of β-amyloid, AMYPAD will provide a unique opportunity to achieve 3 major goals:
1) improve the diagnostic workup of people suspected to have AD and their management;
2) understand the natural history of AD in the pre-symptomatic stage;
3) select people for treatment trials aiming at preventing AD by ensuring a more homogeneous and appropriate enrolment.